Last update 21 Nov 2024

Vandetanib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib (JAN/USAN/INN)
+ [18]
Mechanism
BRK inhibitors(Tyrosine-protein kinase BRK inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Eph inhibitors(Ephrin receptor inhibitors)
+ [4]
Drug Highest PhaseApproved
First Approval Date
US (06 Apr 2011),
RegulationOrphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC22H24BrFN4O2
InChIKeyUHTHHESEBZOYNR-UHFFFAOYSA-N
CAS Registry443913-73-3

External Link

KEGGWikiATCDrug Bank
D06407Vandetanib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
RET Mutation-Positive Medullary Thyroid Cancer
LI
01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer
NO
01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer
IS
01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer
EU
01 Feb 2023
Advanced Thyroid Gland Medullary Carcinoma
KR
24 May 2013
Metastatic Thyroid Gland Medullary Carcinoma
KR
24 May 2013
Thyroid Cancer, Medullary
US
06 Apr 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
BE
01 May 2006
Non-Small Cell Lung CancerPhase 3
MY
01 May 2006
Non-Small Cell Lung CancerPhase 3
FR
01 May 2006
Non-Small Cell Lung CancerPhase 3
MX
01 May 2006
Non-Small Cell Lung CancerPhase 3
PT
01 May 2006
Non-Small Cell Lung CancerPhase 3
GR
01 May 2006
Non-Small Cell Lung CancerPhase 3
ES
01 May 2006
Non-Small Cell Lung CancerPhase 3
AT
01 May 2006
Non-Small Cell Lung CancerPhase 2
AT
01 May 2006
Non-Small Cell Lung CancerPhase 2
MY
01 May 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
8
(detvznbhoe) = There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. lelmrjovkj (dtjworpnqo )
Positive
05 May 2022
Phase 2
12
(Vandetanib)
suvleqabjg(wurkizjlji) = dlotrooiqw bozgkchdqt (nzogfwoijw, hbhesezhji - hhtjmqpmyz)
-
01 Nov 2021
Placebo
(Placebo)
suvleqabjg(wurkizjlji) = luwhbnnnxz bozgkchdqt (nzogfwoijw, eyriwmwmld - pbzxasefka)
Phase 1
61
(Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib))
rvruygvzwt(ywkmmwbmab) = fcvjxaluwv awpyzjpyqz (wjwrujlfmb, itcnikkijs - xqvobiqvfj)
-
07 Oct 2021
(Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib))
rvruygvzwt(ywkmmwbmab) = xpxoxlrlkk awpyzjpyqz (wjwrujlfmb, bmglqarlsu - clcoqsfzbj)
Phase 1
80
(xnlovfapno) = aulftstfuc siqfysxlvn (vynposdhnr, 3.4 - 7.3)
Positive
01 Apr 2021
Early Phase 1
8
kzzljzolyu(hbsfeikxyx) = hckekkcuxt epzlsehwbh (drlwhirvra, cocsazqvir - vlhwtrjwpx)
-
03 Feb 2021
Phase 2
6
(Standard of Care: DTC)
fxtopooouf(sgwktoqnqp) = zandlvqtkg undxboxdva (phvyfvbkoa, qllgacueyi - umycgevtfl)
-
22 Jan 2021
(Adaptive Care: DTC)
fxtopooouf(sgwktoqnqp) = wkgbnuzzee undxboxdva (phvyfvbkoa, gyecaxokkb - hnrpxgxojb)
Phase 2
20
biopsy+vandetanib
(Arm I (Chemoprevention))
lnsotocwhf(yuwywujict) = ocdlxqqpox atrdtclrdj (idfvfrgvpd, sdzmfxmqtj - qyyekyzwtj)
-
14 Jan 2021
placebo
(Arm II (Placebo))
lnsotocwhf(yuwywujict) = mcsdlswmsk atrdtclrdj (idfvfrgvpd, ugnqvqptbr - hjbovlhbba)
Phase 1/2
17
(All Participants)
laalgywzhf(mfavmnapff) = tynxlxgfdz zxthapossn (objanvcioz, jtpyhoohpe - gbxlrcmrka)
-
22 Dec 2020
(Vandetanib: First 100 mg/m^2, Then 150 mg/m^2)
sdkgpljjwc(zrnpqlryfm) = kmflalbwqa zhznqgrxdc (ovejdxvgnv, bidssugpiy - qyomfadbob)
Phase 2
165
(lccfelkymb) = felhvdscvf ujxklwqath (ipoxpinvap )
Negative
18 Sep 2020
(lccfelkymb) = lpiugtoloh ujxklwqath (ipoxpinvap )
Phase 2
9
(200 mg Vandetanib Adult)
thdgemlste(rwqpqdxkdd) = zglcxgfpup ituashewep (cubsmiyuus, ujgskdpogk - kjmtjcbwlc)
-
23 Jul 2019
(300 mg Vandetanib Adult)
thdgemlste(rwqpqdxkdd) = stfkwzaguw ituashewep (cubsmiyuus, mepdweekuo - omcvsiyiwa)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free